Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Tim A. Jolley"'
Autor:
Stephen Abbott, Elizabeth Akoth, Zayani Sims, A. Osinusi, Gebeyehu Teferi, Rachel Silk, Mary Ann McLaughlin, Amy Nelson, Cassie Seamon, Anita Kohli, Henry Masur, Shyam Kottilil, Eric G. Meissner, Angie Price, Hongmei Mo, Jose Chavez, Chloe Gross, Sarah Kattakuzhy, Eleanor Wilson, Lydia Tang, Michael A. Polis, Sreetha Sidharthan, Tim A. Jolley, Benjamin Emmanuel, Michael A. Proschan
Publikováno v:
Annals of internal medicine. 163(12)
Background Treatment of chronic hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) for 6 weeks achieves sustained virologic response (SVR) rates of 95% in some patients. If effective, shorter therapeutic courses could improve adhe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef5d0771b611f0bcf3eca18cb938dbaa
https://pubmed.ncbi.nlm.nih.gov/26595450
https://pubmed.ncbi.nlm.nih.gov/26595450
Autor:
Gabbie Diaz, Phillip S. Pang, Eric G. Meissner, Eva Herrmann, David E. Kleiner, Colleen Kotb, Shyam Kottilil, Miriam M. Marti, Brad Wood, Jose Chavez, Gebeyehu Teferi, Zayani Sims, Michael A. Polis, Henry Masur, Michael A. Proschan, Richard Kwan, Amy Nelson, Rama Kapoor, Anthony S. Fauci, Stephen Abbott, G. Mani Subramanian, Michael C. Sneller, Emily E. Spurlin, Tess Petersen, D'Andrea Egerson, Anita Kohli, Chloe Gross, Kerry Townsend, A. Osinusi, Sreetha Sidharthan, William T. Symonds, Tim A. Jolley, Rachel Silk, John G. McHutchison, Lisa L Barrett, Dimitra Bon, Rohit Talwani
Summary Background Direct-acting antiviral drugs have a high cure rate and favourable tolerability for patients with hepatitis C virus (HCV). Shorter courses could improve affordability and adherence. Sofosbuvir and ledipasvir with ribavirin have hig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86273f273c287ec38f8ae9055b43bdfa
https://europepmc.org/articles/PMC4427052/
https://europepmc.org/articles/PMC4427052/
